Eben Tessari Sells 13,389 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Key Points

• Kiniksa Pharmaceuticals COO Eben Tessari sold 13,389 shares worth approximately $477,451.74 on September 5, decreasing his ownership by 23.15%.
• The stock price of Kiniksa Pharmaceuticals reached $36.57 recently, with a market cap of $2.71 billion and a P/E ratio of 914.48.
• Several analysts have expressed positive sentiment, with Jefferies Financial Group raising their target price for Kiniksa from $45.00 to $54.00 and maintaining a "buy" rating.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 13,389 shares of the stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $35.66, for a total value of $477,451.74. Following the completion of the transaction, the chief operating officer owned 44,452 shares of the company's stock, valued at $1,585,158.32. The trade was a 23.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Eben Tessari also recently made the following trade(s):

• On Thursday, September 4th, Eben Tessari sold 85,271 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $35.52, for a total value of $3,028,825.92.
• On Wednesday, September 3rd, Eben Tessari sold 15,091 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $35.50, for a total value of $535,730.50.
• On Monday, August 18th, Eben Tessari sold 16,200 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $33.77, for a total value of $547,074.00.
• On Tuesday, August 5th, Eben Tessari sold 138,614 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $33.20, for a total transaction of $4,601,984.80.
• On Monday, July 14th, Eben Tessari sold 18,900 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $28.72, for a total transaction of $542,808.00.
• On Monday, June 16th, Eben Tessari sold 17,300 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $28.28, for a total transaction of $489,244.00.
• On Wednesday, June 11th, Eben Tessari sold 45,042 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $30.51, for a total transaction of $1,374,231.42.
• On Tuesday, June 10th, Eben Tessari sold 15,506 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $30.46, for a total transaction of $472,312.76.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ:KNSA traded up $0.09 during mid-day trading on Friday, reaching $37.10. 396,031 shares of the company were exchanged, compared to its average volume of 411,524. Kiniksa Pharmaceuticals International, plc has a 1 year low of $17.82 and a 1 year high of $37.34. The firm's 50-day simple moving average is $31.86 and its 200 day simple moving average is $27.08. The firm has a market cap of $2.75 billion, a price-to-earnings ratio of 927.73 and a beta of 0.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%.The company had revenue of $156.80 million for the quarter, compared to analysts' expectations of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, research analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

KNSA has been the subject of a number of research analyst reports. Wedbush restated an "outperform" rating and set a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Wells Fargo & Company raised their price objective on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, July 9th. Jefferies Financial Group upped their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, July 29th. Finally, Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a report on Sunday, September 7th. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Kiniksa Pharmaceuticals International currently has a consensus rating of "Buy" and an average target price of $41.17.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of large investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC raised its holdings in Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock valued at $25,000 after acquiring an additional 532 shares in the last quarter. Osaic Holdings Inc. purchased a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter valued at approximately $31,000. GAMMA Investing LLC raised its holdings in shares of Kiniksa Pharmaceuticals International by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after purchasing an additional 568 shares in the last quarter. US Bancorp DE purchased a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth $33,000. Finally, Quantbot Technologies LP acquired a new position in shares of Kiniksa Pharmaceuticals International during the second quarter worth $43,000. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.